166 related articles for article (PubMed ID: 27545059)
1. [A STUDY OF INSPIRATORY RESISTANCE OF DRY POWDER INHALER OF AGENTS FOR ASTHMA CONTROL].
Suda S; Konno R; Kurosawa H; Tamura G
Arerugi; 2016 Jul; 65(7):932-6. PubMed ID: 27545059
[TBL] [Abstract][Full Text] [Related]
2. Assessment of inhalation flow patterns of soft mist inhaler co-prescribed with dry powder inhaler using inspiratory flow meter for multi inhalation devices.
Hira D; Koide H; Nakamura S; Okada T; Ishizeki K; Yamaguchi M; Koshiyama S; Oguma T; Ito K; Funayama S; Komase Y; Morita SY; Nishiguchi K; Nakano Y; Terada T
PLoS One; 2018; 13(2):e0193082. PubMed ID: 29462195
[TBL] [Abstract][Full Text] [Related]
3. Effect of Disease Severity in Asthma and Chronic Obstructive Pulmonary Disease on Inhaler-Specific Inhalation Profiles Through the ELLIPTA® Dry Powder Inhaler.
Prime D; de Backer W; Hamilton M; Cahn A; Preece A; Kelleher D; Baines A; Moore A; Brealey N; Moynihan J
J Aerosol Med Pulm Drug Deliv; 2015 Dec; 28(6):486-97. PubMed ID: 26372467
[TBL] [Abstract][Full Text] [Related]
4. Identifying the features of an easy-to-use and intuitive dry powder inhaler for asthma and chronic obstructive pulmonary disease therapy: results from a 28-day device handling study, and an airflow resistance study.
Virchow JC; Weuthen T; Harmer QJ; Jones S
Expert Opin Drug Deliv; 2014 Dec; 11(12):1849-57. PubMed ID: 25151851
[TBL] [Abstract][Full Text] [Related]
5. Minimal inspiratory flow from dry powder inhalers according to a biphasic model of pressure vs. flow relationship.
Kanabuchi K; Kondo T; Tanigaki T; Tajiri S; Hayama N; Takahari Y; Iwao K
Tokai J Exp Clin Med; 2011 Apr; 36(1):1-4. PubMed ID: 21547884
[TBL] [Abstract][Full Text] [Related]
6. [The relationship between inspiratory pressure and flow through dry powder inhaler available in Japan].
Kondo T; Tanigaki T; Tazaki G; Watanabe H; Ishii H; Tsunoda T; Uruma T
Arerugi; 2010 Aug; 59(8):950-5. PubMed ID: 20820136
[TBL] [Abstract][Full Text] [Related]
7. The clinical relevance of dry powder inhaler performance for drug delivery.
Demoly P; Hagedoorn P; de Boer AH; Frijlink HW
Respir Med; 2014 Aug; 108(8):1195-203. PubMed ID: 24929253
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of dry powder inhalers with a focus on ease of use and user preference in inhaler-naïve individuals.
von Schantz S; Katajavuori N; Antikainen O; Juppo A
Int J Pharm; 2016 Jul; 509(1-2):50-58. PubMed ID: 27208655
[TBL] [Abstract][Full Text] [Related]
9. A Preference Study of Two Placebo Dry Powder Inhalers in Adults with COPD: ELLIPTA® Dry Powder Inhaler (DPI) versus DISKUS® DPI.
Yun Kirby S; Zhu CQ; Kerwin EM; Stanford RH; Georges G
COPD; 2016; 13(2):167-75. PubMed ID: 26516724
[TBL] [Abstract][Full Text] [Related]
10. Measurement of peak inspiratory flow with in-check dial device to simulate low-resistance (Diskus) and high-resistance (Turbohaler) dry powder inhalers in children with asthma.
Amirav I; Newhouse MT; Mansour Y
Pediatr Pulmonol; 2005 May; 39(5):447-51. PubMed ID: 15765541
[TBL] [Abstract][Full Text] [Related]
11. [The efficacy of Turbuhaler dry powder inhaler in Japanese asthma--measurement of peak inspiratory flow when using Turbuhaler].
Kaneko N; Narushima M; Tanaka K; Suzuki H
Arerugi; 1996 Jul; 45(7):649-54. PubMed ID: 8831169
[TBL] [Abstract][Full Text] [Related]
12. [Peak inspiratory flow generated through different analogue dry powder inhalers in Shenzhen healthy preschool children].
Zhang QL; Zheng JP; Pan WH; He H; Chen GL; An JY; Yuan LF; Luo DF
Zhonghua Er Ke Za Zhi; 2008 Feb; 46(2):98-103. PubMed ID: 19099680
[TBL] [Abstract][Full Text] [Related]
13. Inhalation characteristics of asthma patients, COPD patients and healthy volunteers with the Spiromax® and Turbuhaler® devices: a randomised, cross-over study.
Azouz W; Chetcuti P; Hosker H; Saralaya D; Chrystyn H
BMC Pulm Med; 2015 May; 15():47. PubMed ID: 25927483
[TBL] [Abstract][Full Text] [Related]
14. The ELLIPTA® Dry Powder Inhaler: Design, Functionality, In Vitro Dosing Performance and Critical Task Compliance by Patients and Caregivers.
Grant AC; Walker R; Hamilton M; Garrill K
J Aerosol Med Pulm Drug Deliv; 2015 Dec; 28(6):474-85. PubMed ID: 26372466
[TBL] [Abstract][Full Text] [Related]
15. Qualitative assessment of attributes and ease of use of the ELLIPTA™ dry powder inhaler for delivery of maintenance therapy for asthma and COPD.
Svedsater H; Dale P; Garrill K; Walker R; Woepse MW
BMC Pulm Med; 2013 Dec; 13():72. PubMed ID: 24314123
[TBL] [Abstract][Full Text] [Related]
16. Total emitted dose of salbutamol sulphate at different inhalation flows and inhalation volumes through different types of dry powder inhalers.
Boshra MS; Almeldien AG; Salah Eldin R; Elberry AA; Abdelwahab NS; Nabil Salem M; Rabea H; Abdelrahim MEA
Exp Lung Res; 2018; 44(4-5):211-216. PubMed ID: 30346848
[TBL] [Abstract][Full Text] [Related]
17. Exhalation immediately before inhalation optimizes dry powder inhaler use.
Kondo T; Hibino M; Tanigaki T; Ohe M; Kato S
J Asthma; 2015; 52(9):935-9. PubMed ID: 26513654
[TBL] [Abstract][Full Text] [Related]
18. In Vitro Dosing Performance of the ELLIPTA® Dry Powder Inhaler Using Asthma and COPD Patient Inhalation Profiles Replicated with the Electronic Lung (eLung™).
Hamilton M; Leggett R; Pang C; Charles S; Gillett B; Prime D
J Aerosol Med Pulm Drug Deliv; 2015 Dec; 28(6):498-506. PubMed ID: 26372465
[TBL] [Abstract][Full Text] [Related]
19. [Measurement of inspiratory flow for the selection of the inhalation treatment device for asthma and COPD].
Plavec D; Gluncić TJ; Gudelj I; Mise K
Lijec Vjesn; 2012; 134(3-4):84-9. PubMed ID: 22768682
[TBL] [Abstract][Full Text] [Related]
20. [New dry powder inhalers].
Emeryk A; Pirożyński M
Pneumonol Alergol Pol; 2015; 83(1):83-7. PubMed ID: 25577539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
